Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by UBS AG in a report issued on Monday, www.benzinga.com reports. They presently have a $172.00 price target on the specialty pharmaceutical company’s stock, down from their previous price target of $175.00. UBS AG’s target price would suggest a potential upside of 16.30% from the company’s current price.

A number of other equities analysts also recently issued reports on the company. BMO Capital Markets restated a “buy” rating and issued a $196.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, September 20th. J P Morgan Chase & Co restated a “buy” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Monday, September 18th. Royal Bank Of Canada restated a “buy” rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Friday, September 15th. Cantor Fitzgerald restated a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, August 29th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 30th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nineteen have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $181.14.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded up 1.09% during mid-day trading on Monday, hitting $149.50. The company’s stock had a trading volume of 239,351 shares. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The stock’s 50 day moving average price is $148.82 and its 200 day moving average price is $150.52. The company has a market cap of $8.98 billion, a price-to-earnings ratio of 23.03 and a beta of 1.13.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.85 by ($0.13). The firm had revenue of $394.39 million during the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the business earned $2.67 earnings per share. Equities analysts forecast that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Jazz Pharmaceuticals PLC’s (JAZZ) “Buy” Rating Reaffirmed at UBS AG” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/25/jazz-pharmaceuticals-plc-jazz-price-target-lowered-to-172-00-at-ubs-ag.html.

In other news, EVP Suzanne Sawochka Hooper sold 4,580 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $160.00, for a total transaction of $732,800.00. Following the completion of the transaction, the executive vice president now owns 32,322 shares in the company, valued at $5,171,520. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction dated Monday, July 17th. The shares were sold at an average price of $154.97, for a total value of $30,994.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 8,297 shares of company stock worth $1,279,417. Insiders own 4.30% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Toronto Dominion Bank grew its position in shares of Jazz Pharmaceuticals PLC by 12.4% during the second quarter. Toronto Dominion Bank now owns 736 shares of the specialty pharmaceutical company’s stock valued at $114,000 after purchasing an additional 81 shares in the last quarter. US Bancorp DE grew its position in shares of Jazz Pharmaceuticals PLC by 94.4% during the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 368 shares in the last quarter. Envestnet Asset Management Inc. grew its position in shares of Jazz Pharmaceuticals PLC by 43.0% during the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock valued at $141,000 after purchasing an additional 295 shares in the last quarter. Gargoyle Investment Advisor L.L.C. purchased a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $206,000. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at about $211,000. Hedge funds and other institutional investors own 88.24% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.